Nkarta Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
103
- Stock Symbol
-
NKTX
- Share Price
-
$1.14
- (As of Friday Closing)
Nkarta Therapeutics General Information
Description
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Contact Information
Website
www.nkartatx.comCorporate Office
- 1150 Veterans Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 1150 Veterans Boulevard
- South San Francisco, CA 94080
- United States
Nkarta Therapeutics Stock Performance
As of 20-Nov-2026, Nkarta Therapeutics’s stock price is $1.14. Its current market cap is $81.3M with 71.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.14 | $1.12 | $1.10 - $3.72 | $81.3M | 71.6M | 1.02M | -$1.73 |
Nkarta Therapeutics Financials Summary
As of 30-Sep-2026, Nkarta Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 78,432 | (74,292) | (21,890) | 137,729 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (130,467) | (110,378) | (118,907) | (125,708) |
| Net Income | (128,935) | (104,084) | (108,790) | (117,501) |
| Total Assets | 308,461 | 404,209 | 501,203 | 378,885 |
| Total Debt | 72,037 | 76,420 | 80,273 | 88,339 |
Nkarta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nkarta Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Nkarta Therapeutics Comparisons
Industry
Financing
Details
Nkarta Therapeutics Competitors (35)
One of Nkarta Therapeutics’s 35 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| ArsenalBio | Venture Capital-Backed | South San Francisco, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Nkarta Therapeutics Patents
Nkarta Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112371-A2 | Modulation of immune cell gene expression | Pending | 25-Nov-2024 | ||
| WO-2026112371-A3 | Modulation of immune cell gene expression | Pending | 25-Nov-2024 | ||
| US-20260144874-A1 | Compositions for treatment of autoimmune diseases | Pending | 09-Oct-2024 | ||
| WO-2026080586-A1 | Compositions for treatment of autoimmune diseases | Pending | 09-Oct-2024 | ||
| WO-2025171147-A1 | Transmembrane proteins and related compositions and uses | Pending | 09-Feb-2024 | C07K14/5443 |
Nkarta Therapeutics Signals
Nkarta Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nkarta Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Nkarta Therapeutics FAQs
-
When was Nkarta Therapeutics founded?
Nkarta Therapeutics was founded in 2015.
-
Where is Nkarta Therapeutics headquartered?
Nkarta Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Nkarta Therapeutics?
Nkarta Therapeutics has 103 total employees.
-
What industry is Nkarta Therapeutics in?
Nkarta Therapeutics’s primary industry is Biotechnology.
-
Is Nkarta Therapeutics a private or public company?
Nkarta Therapeutics is a Public company.
-
What is Nkarta Therapeutics’s stock symbol?
The ticker symbol for Nkarta Therapeutics is NKTX.
-
What is the current stock price of Nkarta Therapeutics?
As of 20-Nov-2026 the stock price of Nkarta Therapeutics is $1.14.
-
What is the current market cap of Nkarta Therapeutics?
The current market capitalization of Nkarta Therapeutics is $81.3M.
-
Who are Nkarta Therapeutics’s competitors?
Fate Therapeutics, Lyell Immunopharma, Aura Biosciences, ArsenalBio, and Arvinas are some of the 35 competitors of Nkarta Therapeutics.
-
What is Nkarta Therapeutics’s annual earnings per share (EPS)?
Nkarta Therapeutics’s EPS for 12 months was -$1.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process